Alnylam Pharmaceuticals Receives 'Buy' Rating from Chardan Capital

Analysts at Chardan Capital reaffirmed a "buy" rating for the shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) in a report released on Friday. The firm has set a price target of $300.00 for the biopharmaceutical company's stock, suggesting a potential upside of 18.30% from its current trading price.

Other analysts have also recently published their evaluations of Alnylam Pharmaceuticals. For instance, StockNews.com reduced its rating from "buy" to "hold" on the same day. Conversely, Bank of America increased its price target from $302.00 to $325.00 while maintaining a "buy" rating. Furthermore, Canaccord Genuity Group raised their price target slightly from $384.00 to $385.00, also labeling the stock as a "buy" in a report earlier this month. Needham & Company LLC confirmed their "buy" rating along with a price objective of $320.00 in a report issued in late February. Finally, HC Wainwright increased their price target from $400.00 to $500.00, also granting a "buy" rating for Alnylam Pharmaceuticals.

Overall, analysis shows that one analyst rates the stock as a "sell," six have given it a "hold" rating, and nineteen analysts recommend it as a "buy." The average rating for Alnylam Pharmaceuticals stock stands at "Moderate Buy", with a consensus price target set at $304.74 according to data compiled by MarketBeat.

Current Stock Performance

Opening at $253.60 on Friday, Alnylam Pharmaceuticals holds a market capitalization of approximately $32.83 billion. The company's stock has a price-to-earnings ratio of -116.87 and a beta of 0.39. Its debt-to-equity ratio is reported at 15.27, with a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals has shown significant price movements over the past year, with the stock reaching a 1-year low of $141.98 and a high of $304.39.

Recently, the company released its earnings results, indicating a loss of ($0.65) earnings per share (EPS) for the last quarter. This figure fell short of analysts' expectations, which were centered around a loss of ($0.62) EPS. Moving forward, research analysts predict that Alnylam Pharmaceuticals will report earnings of -1.7 EPS for the current year.

Insider Trading Activity

In other news related to Alnylam Pharmaceuticals, CEO Yvonne Greenstreet disposed of 1,213 shares of the stock on February 14, selling them at an average price of $255.17, amounting to a total of $309,521.21. Post-transaction, Greenstreet holds 81,526 shares valued at approximately $20.8 million. This represented a 1.47% decrease in her ownership of the stock. Additionally, director Phillip A. Sharp sold 11,250 shares on January 23 at an average price of $275.00, totaling about $3.09 million. In the past 90 days, insiders have sold 71,234 shares worth around $19.96 million, with company insiders currently holding 1.50% of Alnylam’s stock.

Institutional Investor Activity

Significant activity has also been observed among large shareholders. Capital World Investors increased their position in Alnylam Pharmaceuticals by 0.6% during the fourth quarter, making their total ownership 16,600,525 shares worth over $3.9 billion. Vanguard Group also raised its stake by 0.8%, bringing their total holdings to 12,733,399 shares valued at approximately $3.0 billion. Capital Research Global Investors expanded their position by a notable 32.9%, acquiring an additional 1.72 million shares. In addition, Regeneron Pharmaceuticals Inc. purchased a new stake in Alnylam Pharmaceuticals valued at over $1 billion, and T. Rowe Price Investment Management Inc. increased its shares by 39.7%. Current data indicates that institutional investors control about 92.97% of Alnylam Pharmaceuticals' stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative therapies based on ribonucleic acid interference. Their marketed products include ONPATTRO (patisiran) for treating hereditary transthyretin-mediated amyloidosis, AMVUTTRA for hATTR amyloidosis, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1.

Alnylam, Stocks, Investment